Discounted Cash Flow (DCF) Analysis Levered
TScan Therapeutics, Inc. (TCRX)
$6.56
-0.14 (-2.09%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||||
| Operating Cash Flow | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | |||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | |||||||||
| Free Cash Flow | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 6.56 |
|---|---|
| Beta | 0.818 |
| Diluted Shares Outstanding | 24.05 |
| Cost of Debt | |
| Tax Rate | 0.63 |
| After-tax Cost of Debt | 4.23% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.116 |
| Total Debt | 85.98 |
| Total Equity | 157.76 |
| Total Capital | 243.74 |
| Debt Weighting | 35.28 |
| Equity Weighting | 64.72 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - |
| WACC | |||||||||
| PV LFCF | - | - | - | - | - | ||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 6.74 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -34.04 |
| Equity Value | - |
| Shares Outstanding | 24.05 |
| Equity Value Per Share | - |